Hong Kong-listed Innovent Biologics Inc. is partnering with privately held Shenogen Pharma Group Ltd. to develop a combination treatment for advanced cancer.
Under the collaboration, the companies will evaluate Innovent's PD-1 class checkpoint inhibitor Tyvyt in combination with Shenogen Pharma's investigational monoclonal antibody SNG1005 in patients with advanced cancer.
Tyvyt, or sintilimab, is an immuno-oncology therapy jointly developed by Innovent and Indianapolis-based Eli Lilly and Co., and is currently approved to treat classical Hodgkin's lymphoma in China. Innovent CFO Ronnie Ede previously told S&P Global Market Intelligence that the company sold 19,000 units of Tyvyt in the first three weeks following the product's launch in the first quarter of 2019.
Shenogen Pharma has completed multiple mid-stage studies for SNG1005 in the U.S., with a late-stage trial protocol approved by the U.S. Food and Drug Administration.
Shenogen Pharma also owns the full development and commercialization rights to SNG1005 in Greater China. China's National Medical Products Administration has approved its investigational new drug application for SNG1005 in breast cancer which has spread into the brain and a clinical trial is planned.